ASH 2020 | Odronextamab in R/R B-cell non-Hodgkin lymphomas

Rajat Bannerji, MD, PhD, Rutgers Cancer Institute of New Jersey, NJ, discusses the updated results of the Phase I study (NCT02290951) aiming to evaluate the efficacy and safety of odronextamab (REGN1979) in patients with relapsed/refractory (R/R) B-cell non-Hodgkin lymphomas (B-NHL). No dose-limiting toxicities (DLTs) were reported during dose escalation and the maximum tolerated dose was not reached. While treatment-emergent adverse events occurred in most patients, none of them required treatment discontinuation. In patients with R/R follicular lymphoma, odronextamab demonstrated significant therapeutic activity. In R/R diffuse large B-cell lymphoma patients, encouraging activity was observed at higher dose levels, especially in patients with no history of CAR-T treatment. With clear clinical activity and an acceptable safety profile, these findings suggest that odronextamab has potential as a novel single-agent treatment in R/R B-NHLs, including in patients refractory to CAR-T therapy. This interview took place during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020.